Verve Therapeutics, Inc. Quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount in USD from Q3 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
Summary
Verve Therapeutics, Inc. quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount history and growth rate from Q3 2021 to Q2 2024.
  • Verve Therapeutics, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount for the quarter ending June 30, 2024 was $28.2M, a 17.3% decline year-over-year.
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, Quarterly (USD)
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $28.2M -$5.91M -17.3% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $29.7M -$6M -16.8% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $31.1M -$6.12M -16.4% Dec 31, 2023 10-K 2024-02-27
Q3 2023 $32.6M -$6.15M -15.9% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $34.1M +$34.1M Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $35.7M +$35.7M Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $37.2M +$37.2M Dec 31, 2022 10-K 2023-03-02
Q3 2022 $38.8M +$38.7M Sep 30, 2022 10-Q 2022-11-07
Q2 2022 $2K* Jun 30, 2022 10-Q 2022-08-09
Q1 2022 $7K* Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $13K* Dec 31, 2021 10-K 2022-03-14
Q3 2021 $21K* Sep 30, 2021 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.